An investigator-initiated clinical research on the ability of an electroencephalogram analysis program to differentiate between dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) - An investigator-initiated clinical research on the ability of an electroencephalogram analysis program to differentiate between DLB and AD

Department of Behavioral Neurology and Neuropsychiatry, Osaka University United Graduate School of Child Development0 sites40 target enrollmentMarch 11, 2019

Overview

Phase: 未知
Intervention: Not specified
Conditions: Not specified
Sponsor: Department of Behavioral Neurology and Neuropsychiatry, Osaka University United Graduate School of Child Development
Enrollment: 40
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

March 11, 2019

End Date

December 4, 2019

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Department of Behavioral Neurology and Neuropsychiatry, Osaka University United Graduate School of Child Development

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\)Subject or responsible caregiver is unable or unwilling to give informed consent. 2\)Presence of local or diffuse vascular lesions on MRI or CT, where this is thought to be the cause of, or contribute to the severity of the subject's dementia. 3\)Suffering from a significant neurologic disease other than probable DLB or AD. 4\)Systemic diseases possibly contributing to the severity of dementia. 5\)History of alcohol or drug abuse or dependence within the past 2 years. 6\)History of schizophrenia. 7\)Any significant systemic illness or unstable medical condition that may affect EEG. 8\)Use of specific medications: a)Centrally active beta\-blockers (propranolol), methyldopa and clonidine within 4 weeks prior to screening, narcotics. b)Use of anti\-Parkinsonism medications other than levodopacarbidopa, or levodopa benserazide within 4 weeks prior to screening. c)Neuroleptics or narcotic analgesics within 4 weeks prior to screening d)Long acting benzodiazepines or barbiturates within 4 weeks prior to screening e)Use of short\-acting anxiolytics or sedative hypnotics more than 2 times per week within 4 weeks prior to screening. 9\)Patients currently using memantine. Cholinesterase inhibitors are permitted if doses are stable for 4 weeks prior to screening. 10\)Use of any investigational drugs within 30 days or 5 half lives prior to screening. 11\)Subjects who, in the Principal Investigator's opinion, are unlikely to comply with the EEG recording procedure.